- Home
- AU vs ITCI Comparison
AU vs ITCI Comparison
Compare AU & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- ITCI
- Stock Information
- Founded
- AU 1944
- ITCI 2002
- Country
- AU United States
- ITCI United States
- Employees
- AU N/A
- ITCI N/A
- Industry
- AU Precious Metals
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- AU Basic Materials
- ITCI Health Care
- Exchange
- AU Nasdaq
- ITCI Nasdaq
- Market Cap
- AU 10.3B
- ITCI 8.7B
- IPO Year
- AU 1972
- ITCI N/A
- Fundamental
- Price
- AU $26.38
- ITCI $126.89
- Analyst Decision
- AU Hold
- ITCI Buy
- Analyst Count
- AU 5
- ITCI 13
- Target Price
- AU $31.75
- ITCI $100.31
- AVG Volume (30 Days)
- AU 2.5M
- ITCI 2.9M
- Earning Date
- AU 11-07-2024
- ITCI 02-20-2025
- Dividend Yield
- AU 0.84%
- ITCI N/A
- EPS Growth
- AU N/A
- ITCI N/A
- EPS
- AU 1.34
- ITCI N/A
- Revenue
- AU $5,299,000,000.00
- ITCI $613,728,000.00
- Revenue This Year
- AU $31.38
- ITCI $48.41
- Revenue Next Year
- AU $28.36
- ITCI $38.26
- P/E Ratio
- AU $18.96
- ITCI N/A
- Revenue Growth
- AU 17.78
- ITCI 46.08
- 52 Week Low
- AU $15.80
- ITCI $62.78
- 52 Week High
- AU $32.57
- ITCI $128.00
- Technical
- Relative Strength Index (RSI)
- AU 60.56
- ITCI 87.18
- Support Level
- AU $25.26
- ITCI $80.83
- Resistance Level
- AU $26.24
- ITCI $128.00
- Average True Range (ATR)
- AU 0.54
- ITCI 2.57
- MACD
- AU 0.37
- ITCI 4.45
- Stochastic Oscillator
- AU 94.24
- ITCI 97.65
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.